Johns Hopkins University School of Medicine alumnus and former faculty member Hamilton O. Smith, M.D., whose 1978 Nobel Prize-winning discovery of restriction enzymes revolutionized genetic ...
NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...
PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...
Learn why research that continues to look for new substrate alternatives is essential to the future of growing.
Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
According to Nova One Advisor, the global gene editing market size is calculated at USD 11.29 billion in 2025 and is expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback